These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

271 related items for PubMed ID: 24553861

  • 21. Biomarker immunoprofile and molecular characteristics in salivary duct carcinoma: clinicopathological and prognostic implications.
    Santana T, Pavel A, Martinek P, Steiner P, Grossmann P, Baněčková M, Skálová A.
    Hum Pathol; 2019 Nov; 93():37-47. PubMed ID: 31437521
    [Abstract] [Full Text] [Related]

  • 22. Alterations associated with androgen receptor gene activation in salivary duct carcinoma of both sexes: potential therapeutic ramifications.
    Mitani Y, Rao PH, Maity SN, Lee YC, Ferrarotto R, Post JC, Licitra L, Lippman SM, Kies MS, Weber RS, Caulin C, Lin SH, El-Naggar AK.
    Clin Cancer Res; 2014 Dec 15; 20(24):6570-81. PubMed ID: 25316813
    [Abstract] [Full Text] [Related]

  • 23. Prognostic markers in salivary gland cancer and their impact on survival.
    Szewczyk M, Marszałek A, Sygut J, Golusiński P, Golusiński W.
    Head Neck; 2019 Sep 15; 41(9):3338-3347. PubMed ID: 31246357
    [Abstract] [Full Text] [Related]

  • 24. A randomized phase II trial on the addition of dutasteride to combined androgen blockade therapy versus combined androgen blockade therapy alone in patients with advanced or metastatic salivary duct carcinoma - the DUCT study protocol.
    Weijers JAM, Verhaegh GW, Lassche G, van Engen-van Grunsven ACH, Driessen CML, van Erp NP, Jonker MA, Schalken JA, van Herpen CML.
    BMC Cancer; 2024 Sep 20; 24(1):1174. PubMed ID: 39304797
    [Abstract] [Full Text] [Related]

  • 25. Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases.
    Jaehne M, Roeser K, Jaekel T, Schepers JD, Albert N, Löning T.
    Cancer; 2005 Jun 15; 103(12):2526-33. PubMed ID: 15900577
    [Abstract] [Full Text] [Related]

  • 26. Differential expression of hormonal and growth factor receptors in salivary duct carcinomas: biologic significance and potential role in therapeutic stratification of patients.
    Williams MD, Roberts D, Blumenschein GR, Temam S, Kies MS, Rosenthal DI, Weber RS, El-Naggar AK.
    Am J Surg Pathol; 2007 Nov 15; 31(11):1645-52. PubMed ID: 18059220
    [Abstract] [Full Text] [Related]

  • 27. Overexpression of EGFR and absence of C-KIT expression correlate with poor prognosis in salivary gland carcinomas.
    Ettl T, Schwarz S, Kleinsasser N, Hartmann A, Reichert TE, Driemel O.
    Histopathology; 2008 Nov 15; 53(5):567-77. PubMed ID: 18983466
    [Abstract] [Full Text] [Related]

  • 28. Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma: an immunohistochemical analysis of 13 cases and review of the literature.
    Fan CY, Wang J, Barnes EL.
    Am J Surg Pathol; 2000 Apr 15; 24(4):579-86. PubMed ID: 10757407
    [Abstract] [Full Text] [Related]

  • 29. Role of HER2 in Prognosis of Salivary Duct Carcinoma: A Systematic Review and Meta-Analysis.
    Williams CYK, Townson AT, Terry N, Schmitt NC, Sharma A.
    Laryngoscope; 2023 Mar 15; 133(3):476-484. PubMed ID: 35567387
    [Abstract] [Full Text] [Related]

  • 30. Parotid salivary duct carcinoma: a single institution's 20-year experience.
    Stodulski D, Mikaszewski B, Majewska H, Kuczkowski J.
    Eur Arch Otorhinolaryngol; 2019 Jul 15; 276(7):2031-2038. PubMed ID: 31062093
    [Abstract] [Full Text] [Related]

  • 31. Genomic alteration in rare subtype of sarcomatoid salivary duct carcinoma.
    Jeong JS, Cho KJ, Kim D, Lee YS, Song JS.
    Pathol Res Pract; 2021 Dec 15; 228():153678. PubMed ID: 34781210
    [Abstract] [Full Text] [Related]

  • 32. Clinicopathologic study of salivary duct carcinoma and the efficacy of androgen deprivation therapy.
    Yamamoto N, Minami S, Fujii M.
    Am J Otolaryngol; 2014 Dec 15; 35(6):731-5. PubMed ID: 25087467
    [Abstract] [Full Text] [Related]

  • 33. Expression of PTEN, Androgen Receptor, HER2/neu, Cytokeratin 5/6, Estrogen Receptor-Beta, HMGA2, and PLAG1 in Salivary Duct Carcinoma.
    Liang L, Williams MD, Bell D.
    Head Neck Pathol; 2019 Dec 15; 13(4):529-534. PubMed ID: 30390196
    [Abstract] [Full Text] [Related]

  • 34. Intratumoral heterogeneity of HER2 protein and amplification of HER2 gene in salivary duct carcinoma.
    Kondo Y, Kikuchi T, Esteban JC, Kumaki N, Ogura G, Inomoto C, Hirabayashi K, Kajiwara H, Sakai A, Sugimoto R, Otsuru M, Okami K, Tsukinoki K, Nakamura N.
    Pathol Int; 2014 Sep 15; 64(9):453-9. PubMed ID: 25209856
    [Abstract] [Full Text] [Related]

  • 35. A 20-Year Review of 75 Cases of Salivary Duct Carcinoma.
    Gilbert MR, Sharma A, Schmitt NC, Johnson JT, Ferris RL, Duvvuri U, Kim S.
    JAMA Otolaryngol Head Neck Surg; 2016 May 01; 142(5):489-95. PubMed ID: 26939990
    [Abstract] [Full Text] [Related]

  • 36. Salivary Duct Carcinoma: An Update on Morphologic Mimics and Diagnostic Use of Androgen Receptor Immunohistochemistry.
    Udager AM, Chiosea SI.
    Head Neck Pathol; 2017 Sep 01; 11(3):288-294. PubMed ID: 28321773
    [Abstract] [Full Text] [Related]

  • 37. Expression of mitotic checkpoint proteins BUB1B and MAD2L1 in salivary duct carcinomas.
    Ko YH, Roh JH, Son YI, Chung MK, Jang JY, Byun H, Baek CH, Jeong HS.
    J Oral Pathol Med; 2010 Apr 01; 39(4):349-55. PubMed ID: 20040022
    [Abstract] [Full Text] [Related]

  • 38. Immunohistochemical Reactivity of Prostate-Specific Markers for Salivary Duct Carcinoma.
    Takada N, Nishida H, Oyama Y, Kusaba T, Kadowaki H, Arakane M, Wada J, Urabe S, Daa T.
    Pathobiology; 2020 Apr 01; 87(1):30-36. PubMed ID: 31865345
    [Abstract] [Full Text] [Related]

  • 39. Biomarker immunoprofile in salivary duct carcinomas: clinicopathological and prognostic implications with evaluation of the revised classification.
    Takase S, Kano S, Tada Y, Kawakita D, Shimura T, Hirai H, Tsukahara K, Shimizu A, Imanishi Y, Ozawa H, Okami K, Sato Y, Sato Y, Fushimi C, Okada T, Sato H, Otsuka K, Watanabe Y, Sakai A, Ebisumoto K, Togashi T, Ueki Y, Ota H, Hanazawa T, Chazono H, Osamura RY, Nagao T.
    Oncotarget; 2017 Aug 29; 8(35):59023-59035. PubMed ID: 28938615
    [Abstract] [Full Text] [Related]

  • 40. Expression of androgen receptor, gross cystic disease fluid protein, and CD44 in salivary duct carcinoma.
    Kapadia SB, Barnes L.
    Mod Pathol; 1998 Nov 29; 11(11):1033-8. PubMed ID: 9831198
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.